Autolus Therapeutics Plc (AUTL)
1.19
-0.04
(-3.64%)
USD |
NASDAQ |
Nov 12, 16:00
1.21
+0.02
(+1.68%)
After-Hours: 07:07
Autolus Therapeutics Enterprise Value : 508.24M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 508.24M |
| November 11, 2026 | 520.23M |
| November 10, 2026 | 542.87M |
| November 09, 2026 | 542.87M |
| November 06, 2026 | 532.21M |
| November 05, 2026 | 526.89M |
| November 04, 2026 | 558.85M |
| November 03, 2026 | 568.17M |
| November 02, 2026 | 569.50M |
| October 30, 2026 | 596.14M |
| October 29, 2026 | 612.12M |
| October 28, 2026 | 625.43M |
| October 27, 2026 | 604.13M |
| October 26, 2026 | 598.80M |
| October 23, 2026 | 601.46M |
| October 22, 2026 | 612.12M |
| October 21, 2026 | 622.77M |
| October 20, 2026 | 633.42M |
| October 19, 2026 | 614.78M |
| October 16, 2026 | 617.44M |
| October 15, 2026 | 649.40M |
| October 14, 2026 | 641.41M |
| October 13, 2026 | 622.77M |
| October 12, 2026 | 654.73M |
| October 09, 2026 | 673.37M |
| Date | Value |
|---|---|
| October 08, 2026 | 662.72M |
| October 07, 2026 | 673.37M |
| October 06, 2026 | 668.05M |
| October 05, 2026 | 678.70M |
| October 02, 2026 | 665.38M |
| October 01, 2026 | 684.03M |
| September 30, 2026 | 708.00M |
| September 29, 2026 | 659.75M |
| September 28, 2026 | 659.75M |
| September 25, 2026 | 658.42M |
| September 24, 2026 | 673.06M |
| September 23, 2026 | 683.70M |
| September 22, 2026 | 705.00M |
| September 21, 2026 | 681.04M |
| September 18, 2026 | 681.04M |
| September 17, 2026 | 675.72M |
| September 16, 2026 | 662.41M |
| September 15, 2026 | 667.73M |
| September 14, 2026 | 681.04M |
| September 11, 2026 | 665.07M |
| September 10, 2026 | 686.36M |
| September 09, 2026 | 705.00M |
| September 08, 2026 | 726.29M |
| September 04, 2026 | 760.89M |
| September 03, 2026 | 774.20M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bicycle Therapeutics Plc | -280.85M |
| Biodexa Pharmaceuticals Plc | -- |
| argenx SE | 60.66B |
| NuCana Plc | -20.99M |
| Mereo BioPharma Group Plc | 23.19M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.06M |
| Revenue (Quarterly) | 41.22M |
| Total Expenses (Quarterly) | 96.28M |
| EPS Diluted (Quarterly) | -0.2068 |
| Gross Profit Margin (Quarterly) | 56.53% |
| Profit Margin (Quarterly) | -133.6% |
| Earnings Yield | -80.80% |
| Normalized Earnings Yield | -80.72 |